Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff
CinRx spinout launches to develop aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism
Picking up one of Roche’s few remaining clinical cardiometabolism assets, Sofinnova Investments has joined Sofinnova Partners, 5AM Ventures and CinRx to launch CinCor with a $50 million series A and exclusive, worldwide rights to the pharma's aldosterone synthase inhibitor.
CinRx President and CEO Jon Isaacsohn told BioCentury the company acquired CIN-107 because of its specificity as an ALDOS inhibitor that does not affect cortisol levels, plus its safety profile. The deal comes several years after Roche began seeking partners for its cardiovascular and metabolism assets after deciding to phase out R&D in these therapeutic areas. The decision followed discontinuation of Type II diabetes program aleglitazar and high-profile CETP inhibitor dalcetrapib (see "New York Translation"). ...